ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. ITB-MED is wholly committed to advancing and exploring the potential of TCD601, with a particular focus on its applications in transplantation and autoimmunity. The efforts extend to comprehensive worldwide clinical trials. ITB-MED is actively investigating further preclinical therapies to expand the reach of its novel immune-modulating approaches.
Looking for a particular ITBMed employee's phone or email?
ITBMed Questions
The ITBMed annual revenue was $600000 in 2026.
Matthew Lamb is the Chief Executive Officer (Interim) and Chief Operating Officer of ITBMed.
28 people are employed at ITBMed.
ITBMed is based in New York, New York.
The NAICS codes for ITBMed are [3254, 32, 325414, 32541, 325].
The SIC codes for ITBMed are [283, 28].
Top ITBMed Employees
-
Matthew Lamb
Chief Executive Officer (Interim) and Chief Operating Officer at ITBMed
Washington Township, NJ, US24 -
Marsha Miller
Vice President, Head of Regulatory Affairs at ITBMed
Allentown, PA, US24 -
15+
-
23
-
Julie Gatti
Director, Head of Data Management at ITBMed
United States23 -
Gabriela Turcanu
Senior Medical Director Clinical Development at ITBMed
Princeton, NJ, US23 -
Fredrik Juhlin
Director Clinical Operations at ITBMed
Stockholm, SE21 -
Andreas Fasth
Clinical Development Director at ITBMed
Stockholm, SE2 -
Leslie Zacks
Chief Legal and Compliance Officer at ITBMed
New York, NY, US35+
Related Companies
